Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. (Q51540764)

6 April 2018

title

Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. (English)

1 reference

6 April 2018

0 references

Peter Laszlo Lakatos

1

1 reference

6 April 2018

Lajos Sandor Kiss

2

1 reference

6 April 2018

Karoly Palatka

3

1 reference

6 April 2018

Istvan Altorjay

4

1 reference

6 April 2018

Peter Antal-Szalmas

5

1 reference

6 April 2018

Eszter Palyu

6

1 reference

6 April 2018

Miklos Udvardy

7

1 reference

6 April 2018

Tamas Molnar

8

1 reference

6 April 2018

Klaudia Farkas

9

1 reference

6 April 2018

Gabor Veres

10

1 reference

6 April 2018

Jolan Harsfalvi

11

1 reference

6 April 2018

Janos Papp

12

1 reference

6 April 2018

Maria Papp

13

1 reference

6 April 2018

publication date

23 September 2010

1 reference

6 April 2018

Inflammatory Bowel Diseases

published in

1 reference

6 April 2018

volume

17

1 reference

6 April 2018

issue

3

1 reference

6 April 2018

page(s)

767-777

1 reference

6 April 2018

Laboratory markers in IBD: useful, magic, or unnecessary toys?

cites work

1 reference

C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study

21 January 2018

1 reference

Biomarkers to improve diagnostic and prognostic accuracy in systemic infections

21 January 2018

1 reference

Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids

21 January 2018

1 reference

The role of lipopolysaccharide-binding protein in modulating the innate immune response

21 January 2018

1 reference

Interactions among genes influencing bacterial recognition increase IBD risk in a population-based New Zealand cohort.

21 January 2018

1 reference

Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.

21 January 2018

1 reference

Analysis of Cd14 as a genetic modifier of experimental inflammatory bowel disease (IBD) in mice.

21 January 2018

1 reference

Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis.

21 January 2018

1 reference

Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.

21 January 2018

1 reference

Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites

21 January 2018

1 reference

Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?

21 January 2018

1 reference

Anti-microbial antibodies in celiac disease: trick or treat?

21 January 2018

1 reference

Disease activity courses in a regional cohort of Crohn's disease patients.

21 January 2018

1 reference

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease

21 January 2018

1 reference

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease

21 January 2018

1 reference

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

21 January 2018

1 reference

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.21402

1 reference

6 April 2018

PubMed ID

20865702

1 reference

6 April 2018